The addition of biologic therapy to the medical armamentarium has revolutionized the management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Deciding which patients would benefit from surgery and choosing the “right” biologic remain a challenge. This session will provide an up-to-date analysis of the current literature and guidelines to help in the decision process. Through case examples and videos, the panel of experts will address the role of biomarkers in CRSwNP; management of patients with common comorbid conditions such as asthma, Aspirin Exacerbated Respiratory Disease (AERD) and eosinophilic granulomatosis with polyangiitis (EGPA); and provide practical recommendations to successfully prescribe and follow patients on biologic therapy. In addition, the panel will share their expertise and surgical pearls in performing functional endoscopic sinus surgery (FESS) in the era of biologics to optimize outcomes and facilitate the delivery of topical medications in patients with CRSwNP that require multifaceted therapy.